Mobia Medical (NASDAQ:MOBI) Director Casey Tansey Acquires 15,821 Shares

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 15,821 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $11.66 per share, for a total transaction of $184,472.86. Following the completion of the purchase, the director owned 284,725 shares of the company’s stock, valued at approximately $3,319,893.50. The trade was a 5.88% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Mobia Medical Price Performance

Shares of NASDAQ:MOBI opened at $11.74 on Tuesday. The firm’s fifty day moving average is $12.42. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80. The company has a market capitalization of $390.84 million and a P/E ratio of -0.61. Mobia Medical, Inc. has a 1-year low of $10.19 and a 1-year high of $15.29.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The company had revenue of $13.51 million for the quarter. Mobia Medical’s quarterly revenue was up 102.4% on a year-over-year basis. On average, sell-side analysts anticipate that Mobia Medical, Inc. will post -2.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

MOBI has been the topic of a number of recent analyst reports. Wolfe Research assumed coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They set an “outperform” rating on the stock. Zacks Research raised Mobia Medical to a “hold” rating in a report on Wednesday, June 3rd. The Goldman Sachs Group initiated coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 price target for the company. Bank of America began coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Wall Street Zen upgraded Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Mobia Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.75.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.